People With Type 2 Diabetes Have a Greater Risk of Cardiovascular Disease Even With Risk Factors Optimally Controlled
December 02, 2020 02:30pm
Read about the new Rx products featured in December 2016.
Marketed by:Napo Pharmaceuticals
Indication:Mytesi (crofelemer) has been launched as the only FDA-approved treatment for the relief of non-infectious diarrhea in patients with HIV.
Dosage Form:Tablets: 125 mg
For More Information:napopharma.com
Marketed by:Validus Pharmaceuticals LLC
Indication:The FDA has approved Equetro (carbamazepine) for the treatment of pain associated with trigeminal neuralgia and as an antiepileptic drug for the treatment of partial seizures with complex symptomatology, generalized tonic-clonic seizures, and mixed seizures.
Dosage Form:Extended-release capsules: 100, 200, and 300 mg
For More Information:equetro.com
Indication:The FDA has approved Tecentriq (atezolizumab) as the first, and only, anti-PDL1 cancer immunotherapy for metastatic non—small cell lung cancer.
Dosage Form:Injection: 1200 mg/20 mL (60 mg/mL) solution in a single-dose vial
For More Information:gene.com